JAZZ Stock Analysis: Buy, Sell, or Hold?
JAZZ - Jazz Pharmaceuticals, Inc.
$182.69
-6.46 (-3.42%)
▼
5d:
+1.15%
30d:
-3.32%
90d:
+6.81%
BUY
MODERATE Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 05, 2026
Get Alerted When JAZZ Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: JAZZ shows positive signals but monitor for confirmation. Market pricing in 1.2% decline. Moderate conviction.
💡 BUY OPPORTUNITY: JAZZ shows positive signals but monitor for confirmation. Market pricing in 1.2% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$231.79
Based on 4.1% avg growth
INTRINSIC VALUE TODAY
$143.92
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: JAZZ is currently trading at $182.69, which is considered slightly high relative to its 30-day fair value range of $173.52 to $188.58. The stock's valuation (Forward PE: 7.3) is in line with its historical norms (7.6). Remarkably, the market is currently pricing in an annual earnings decline of 1.2% over the next few years. This pessimistic expectation contrasts with the company's recent 3.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, JAZZ is in a uptrend. The price is currently testing key support at $178.32. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: JAZZ has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $223.50 (+22.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, JAZZ is in a uptrend. The price is currently testing key support at $178.32. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: JAZZ has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $223.50 (+22.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$173.52 -
$188.58
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
71.4%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.4%)
- BULLISH: Trading 22.3% below Wall St target ($223.50)
Fair Price Analysis
30-Day Fair Range
$173.52 -
$188.58
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$178.32
Resistance Level
$191.28
Current Trend
Uptrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.32
Wall Street Target
$223.50
(+22.3%)
Revenue Growth (YoY)
10.1%
Earnings Growth (YoY)
3.2%
Profit Margin
-8.3%
Valuation Discount vs History
-1.2% cheaper
PE vs Historical
7.3 vs 7.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.2%
(market-implied from PE analysis)
1-Year Target
$180.50
(-1%)
2-Year Target
$178.33
(-2%)
3-Year Target
$176.19
(-4%)
3-Yr Target (if PE normalizes)
(PE: 7→8)
$182.86
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 4.2%)
$632.86
(+246%)
Base:
(SPY PE: 7.3, Growth: 4.2%)
$206.89
(+13%)
Bear:
(PE: 6.2, Growth: 4.2%)
$175.86
(-4%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 7.3 to 7.6
Stabilization Target:
$189.60
(+3.8%)
PE Expansion Potential:
+3.8%
Share & Embed Analysis
Last updated: March 30, 2026 7:02 AM ET
Data refreshes hourly during market hours. Next update: 8:02 AM
Data refreshes hourly during market hours. Next update: 8:02 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JAZZ showing a specific setup today?
Insider Activity (6 Months)
0
Buys
15
Sells
Net
INSIDERS SELLING
Recent Transactions
Patricia Carr
SELL
1287 shares
2026-03-09
Norbert G Riedel
SELL
3415 shares
2026-02-27
Patricia Carr
SELL
1117 shares
2026-02-27
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 65 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1018 | 56 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 54 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$132 | 49 HOLD |
Advanced JAZZ Option Strategies
Professional options setups generated by AI based on today's JAZZ price and gamma walls.
